COMy 2017 | COMy 2017: Day 2 discussion on relapsed myeloma, treatment, plasma cell leukemia and awards
This is a round-up of day two of the COMy Multiple Myeloma Highlights 2017 congress with Mohamad Mohty, MD, PhD of Saint-Antoine Hospital and University Pierre & Marie Curie, Paris, France and Arnon Nagler, MD of Chaim Sheba Medical Center, Ramat Gan, Israel. First, Prof. Mohty highlights the excellence awards session; Prof. Dimopoulos and Prof. Rajkumar received the awards and delivered lectures on how the field has moved over the last 15 years and how we are heading towards finding a cure. They then move on to discuss the major topic of day two, which was relapsed myeloma. Prof. Nagler and Prof. Mohty discuss strategies in the relapsed setting and the importance of preventing relapse. Further, they talk about the use of transplantation, monoclonal antibodies (daratumumab, elotuzumab and isatuximab), IMiDs (thalidomide, lenalidomide and pomalidomide), HDAC inhibitors (vorinostat and panobinostat) and proteasome inhibitors (bortezomib, carfilzomib and ixazomib); the sequence of therapy; and plasma cell leukemia. Prof. Mohty highlights the lifetime achievement award given to Prof. Ken Anderson and finally, mentions the Virtual Academy of Myeloma, which is part of the COMy educational initiative and will soon be launching.
Recoded at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
- HDAC inhibitors
- monoclonal antibodies
- plasma cell leukemia
- proteasome inhibitors
- relapsed myeloma
- therapy sequence
- Virtual Academy of Myeloma
Get great new content delivered to your inboxSign up